Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising
Providing an addition modification under the corporate income tax for the amount of certain direct-to-consumer advertising expenses for certain covered drugs paid or incurred during the taxable year that are deducted under the Internal Revenue Code; and applying the Act to all taxable years beginning after December 31, 2025.
1 bill selected
Basic Information
- Status
- Chaptered
- Session
- 2026 Regular Session
- Type
- Unknown
- Cross-filed
- False
Links
- State Link
- View on State Website
- LegiScan URL
- View on LegiScan
Upcoming Events
Hearing
February 12, 2026
at 13:00
📍 Ways and Means
Hearing - Ways and Means Committee
Sponsors
Ziegler
Watson
Feldmark
Terrasa
Addison
Charkoudian
Cullison
Ebersole
Guzzone
Hill
Moreno